There could be more problems in store for Illumina based on its disappointing sneak peek at Q3 revenue.
Shares drop in response to preliminary third-quarter results that came in well short of management's guidance.
The rumors of a $30 billion megamerger likely don’t hold water, but they could still point to some upside in gene-sequencing stocks.
Pacific Biosciences is growing more quickly than Illumina, which is struggling to overcome sluggish demand in Europe.
The cancer-test company continues to increase revenue, resulting in a smaller loss for the second quarter.
Optimism that its latest sequencing machine will catapult the company's sales higher is sparking a rally.
Growth in sequencing array and consumables sales enables this genomic-sequencing leader to post solid Q2 results.
Volume growth from the cancer-test maker was outstanding, and while there's work to go on reimbursement, revenue increased 19% year over year.
A pre-announcement of disappointing first-quarter financials weighed down shares in this gene-sequencing giant.
Sluggish European sales causes the genomic sequencing company to stumble in Q1.